Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $47.99 (-0.02%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 19, 2025 | Annabel Samimy | Stifel Nicolaus | $55.00 | +14.6% |
| Sep 11, 2024 | David Amsellem | Piper Sandler | $36.00 | -25.0% |
| May 24, 2024 | David Amsellem | Piper Sandler | $41.00 | -14.6% |
| Apr 8, 2024 | Irene Buhalo | Jefferies | $40.00 | -16.6% |
| Apr 8, 2024 | Annabel Samimy | Stifel Nicolaus | $38.00 | -20.8% |
Top Analysts Covering SUPN
SUPN vs Sector & Market
| Metric | SUPN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.00 | 2.24 | 2.41 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +25.0% | +1150.2% | +14.9% |
| P/E Ratio | -72.43 | 6.94 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $208M | $211M | $215M | 4 |
| 2026-09-30 | $222M | $226M | $229M | 2 |
| 2026-12-31 | $231M | $235M | $239M | 3 |
| 2027-03-31 | $232M | $236M | $240M | 3 |
| 2027-06-30 | $246M | $250M | $254M | 2 |
| 2027-09-30 | $262M | $267M | $271M | 2 |
| 2027-12-31 | $269M | $274M | $279M | 3 |
| 2028-12-31 | $1.16B | $1.18B | $1.20B | 5 |
| 2029-12-31 | $1.28B | $1.31B | $1.33B | 2 |
| 2030-12-31 | $1.34B | $1.37B | $1.39B | 2 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.37 | $0.42 | $0.47 | 2 |
| 2026-09-30 | $0.59 | $0.60 | $0.62 | 1 |
| 2026-12-31 | $0.69 | $0.71 | $0.73 | 1 |
| 2027-03-31 | $0.45 | $0.47 | $0.48 | 1 |
| 2027-06-30 | $0.67 | $0.69 | $0.71 | 1 |
| 2027-09-30 | $0.90 | $0.92 | $0.94 | 1 |
| 2027-12-31 | $1.01 | $1.03 | $1.06 | 1 |
| 2028-12-31 | $2.40 | $5.34 | $8.28 | 2 |
| 2029-12-31 | $6.74 | $6.91 | $7.06 | 1 |
| 2030-12-31 | $6.84 | $7.01 | $7.17 | 1 |
Frequently Asked Questions
What is the analyst consensus for SUPN?
The consensus among 1 analysts covering Supernus Pharmaceuticals, Inc. (SUPN) is Hold with an average price target of $62.00.
What is the highest price target for SUPN?
The highest price target for SUPN is $55.00, set by Annabel Samimy at Stifel Nicolaus on 2025-12-19.
What is the lowest price target for SUPN?
The lowest price target for SUPN is $36.00, set by David Amsellem at Piper Sandler on 2024-09-11.
How many analysts cover SUPN?
1 analysts have issued ratings for Supernus Pharmaceuticals, Inc. in the past 12 months.
Is SUPN a buy or sell right now?
Based on 1 analyst ratings, SUPN has a consensus rating of Hold (3.00/5) with a +25.0% upside to the consensus target of $62.00.
What are the earnings estimates for SUPN?
Analysts estimate SUPN will report EPS of $0.42 for the period ending 2026-06-30, with revenue estimated at $211M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.